Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patients.
Aromatase inhibitors
Breast neoplasms
Cardiovascular diseases
Carotid plaque
Dyslipidemias
Journal
The Korean journal of internal medicine
ISSN: 2005-6648
Titre abrégé: Korean J Intern Med
Pays: Korea (South)
ID NLM: 8712418
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
01
06
2016
accepted:
03
05
2017
pubmed:
26
8
2017
medline:
21
1
2020
entrez:
26
8
2017
Statut:
ppublish
Résumé
The aromatase inhibitors (AIs) are well known anti-hormonal therapy in endocrine-responsive breast cancer patients. It can lead to dyslipidemia and be the risk factor of cardiovascular disease due to low estrogen level. However, some recent studies comparing AIs with placebo have shown controversial results. The aim of this study was to investigate lipid profiles, measurement of carotid intima-media thickness (IMT) and the presence of plaque among endocrine-responsive breast cancer treated with AIs compared to ones that were not treated with AIs. A total of 85 postmenopausal women, who underwent breast cancer surgery during the age of 50 to 64 without history of statin use were included. There were 42 patients who were treated with AIs over 1 year (group 1) and 43 patients without AIs use (group 2). Serum total cholesterol, high density lipoprotein cholesterol, triglycerides, fasting blood glucose, carotid IMT, and presence of plaque were assessed. The baseline characteristics were similar between two groups and there was no significant difference in carotid IMT irrespective of AIs administration. However, ultrasonographic evaluation of carotid artery revealed that the presence of plaque in AI users was significantly higher than in non-AI users (66.7% vs. 41.9%, p = 0.02; odds ratio, 4.21 in adjusted model; p = 0.01). History of diabetes was also the significant risk factor for the plaque formation. There was no significant difference in lipid profile itself between two groups, but more importantly the presence of the plaque was much higher indicating possible detrimental effect of AI on cardiovascular system.
Sections du résumé
BACKGROUND/AIMS
OBJECTIVE
The aromatase inhibitors (AIs) are well known anti-hormonal therapy in endocrine-responsive breast cancer patients. It can lead to dyslipidemia and be the risk factor of cardiovascular disease due to low estrogen level. However, some recent studies comparing AIs with placebo have shown controversial results. The aim of this study was to investigate lipid profiles, measurement of carotid intima-media thickness (IMT) and the presence of plaque among endocrine-responsive breast cancer treated with AIs compared to ones that were not treated with AIs.
METHODS
METHODS
A total of 85 postmenopausal women, who underwent breast cancer surgery during the age of 50 to 64 without history of statin use were included. There were 42 patients who were treated with AIs over 1 year (group 1) and 43 patients without AIs use (group 2). Serum total cholesterol, high density lipoprotein cholesterol, triglycerides, fasting blood glucose, carotid IMT, and presence of plaque were assessed.
RESULTS
RESULTS
The baseline characteristics were similar between two groups and there was no significant difference in carotid IMT irrespective of AIs administration. However, ultrasonographic evaluation of carotid artery revealed that the presence of plaque in AI users was significantly higher than in non-AI users (66.7% vs. 41.9%, p = 0.02; odds ratio, 4.21 in adjusted model; p = 0.01). History of diabetes was also the significant risk factor for the plaque formation.
CONCLUSION
CONCLUSIONS
There was no significant difference in lipid profile itself between two groups, but more importantly the presence of the plaque was much higher indicating possible detrimental effect of AI on cardiovascular system.
Identifiants
pubmed: 28838227
pii: kjim.2016.205
doi: 10.3904/kjim.2016.205
pmc: PMC6506747
doi:
Substances chimiques
Aromatase Inhibitors
0
Lipids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
579-587Références
Stroke. 1999 Apr;30(4):841-50
pubmed: 10187889
N Engl J Med. 1999 Jun 10;340(23):1801-11
pubmed: 10362825
Am J Epidemiol. 2000 Mar 1;151(5):478-87
pubmed: 10707916
J Epidemiol. 2000 Apr;10(1 Suppl):S10-7
pubmed: 10835823
J Clin Endocrinol Metab. 2000 Jul;85(7):2402-10
pubmed: 10902785
N Engl J Med. 2000 Aug 24;343(8):522-9
pubmed: 10954759
J Clin Oncol. 2001 Jan 1;19(1):37-43
pubmed: 11134193
Eur J Cancer. 2001 Aug;37(12):1510-3
pubmed: 11506958
Am J Cardiol. 2002 Feb 21;89(4A):10B-15B; discussion 15B-16B
pubmed: 11879661
Stroke. 2002 Dec;33(12):2916-22
pubmed: 12468791
Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):355S-61S
pubmed: 14734491
J Clin Oncol. 2005 Jan 20;23(3):619-29
pubmed: 15545664
Stroke. 2005 Jan;36(1):5-8
pubmed: 15569868
Ann Oncol. 2005 May;16(5):707-15
pubmed: 15817595
J Natl Cancer Inst. 2005 Sep 7;97(17):1262-71
pubmed: 16145047
Ann Oncol. 2005 Oct;16(10):1569-83
pubmed: 16148022
Med Clin (Barc). 2005 Dec 3;125(20):770-4
pubmed: 16373026
Clin Breast Cancer. 2006 Feb;6 Suppl 2:S58-64
pubmed: 16595028
J Clin Oncol. 2007 Feb 10;25(5):486-92
pubmed: 17200148
J Natl Cancer Inst. 2007 Mar 7;99(5):365-75
pubmed: 17341728
Cancer. 2008 Jan 15;112(2):260-7
pubmed: 18041059
Lancet Oncol. 2008 Jan;9(1):45-53
pubmed: 18083636
Neurology. 2008 Apr 1;70(14):1200-7
pubmed: 18354078
Atherosclerosis. 2008 Nov;201(1):76-84
pubmed: 18367192
Circulation. 2009 Dec 22;120(25):2567-76
pubmed: 19996016
J Am Coll Cardiol. 2010 Dec 14;56(25):e50-103
pubmed: 21144964
J Natl Cancer Inst. 2011 Sep 7;103(17):1299-309
pubmed: 21743022
Diabetes Care. 2012 Dec;35(12):2640-6
pubmed: 23043165
Diabetes Care. 2013 May;36(5):1327-34
pubmed: 23404302
Breast. 2013 Apr;22(2):121-129
pubmed: 23462682
Cancer Invest. 2014 May;32(4):99-104
pubmed: 24548302
Life Sci. 2015 Mar 1;124:101-9
pubmed: 25623855
Expert Opin Drug Saf. 2015 Aug;14(8):1201-11
pubmed: 26059833
Curr Atheroscler Rep. 2015 Sep;17(9):55
pubmed: 26233633
Diabetes Care. 2015 Oct;38(10):1937-44
pubmed: 26253729
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
CA Cancer J Clin. 1994 Jan-Feb;44(1):7-26
pubmed: 8281473
Radiology. 1993 Aug;188(2):363-70
pubmed: 8327679
Circulation. 1997 Jan 7;95(1):252-64
pubmed: 8994444
Adv Intern Med. 1997;42:39-66
pubmed: 9048116
Stroke. 1997 Mar;28(3):665-71
pubmed: 9056629
Clin Cancer Res. 1998 Sep;4(9):2089-93
pubmed: 9748124
Cas Lek Cesk. 1998 Nov 30;137(23):716-20
pubmed: 9990175